Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsSTU:6IB -6.27%80 Days Payable is 91.50 as of Dec. 2025, which is 13% below its 10-year median of 105.76. GuruFocus rates STU:6IB with a GF Score™ of 80/100 and a GF Value™ of €11.19 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Innovent Biologics ranks worse than 55.41% on this metric.
The historical rank and industry rank for Innovent Biologics's Days Payable or its related term are showing as below:
STU:6IB'
s Days Payable Range Over the Past 10 Years
Min: 87.33 Med: 105.76 Max: 187.05
Current: 88.3
During the past 10 years, Innovent Biologics's highest Days Payable was 187.05. The lowest was 87.33. And the median was 105.76.
STU:6IB's Days Payable is ranked worse than 55.41% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs STU:6IB: 88.30
Innovent Biologics's Days Payable
increased
from Dec. 2024 (62.80) to Dec. 2025 (91.50).
It may suggest that Innovent Biologicsdelayed paying its suppliers.
Innovent Biologics Days Payable Related Terms
Innovent Biologics Days Payable Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6IB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Innovent Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Days Payable distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Innovent Biologics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (STU:6IB) has a Days Payable of 91.50 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Innovent Biologics and its competitors. This is 13% below median its historical median of 105.76. Over the past decade, Innovent Biologics' Days Payable has ranged from 87.33 to 187.05. According to the industry distribution chart, Innovent Biologics ranks #389 out of 702 companies in the Biotechnology industry, placing it in the top 55.4%.
Is Innovent Biologics' Days Payable too high?
Innovent Biologics' current Days Payable of 91.50 is 13% below median its 10-year median of 105.76. Over the past 10 years, this metric has ranged from a low of 87.33 to a high of 187.05. The Biotechnology industry median Days Payable is 113.10. Innovent Biologics' value of 91.50 is 19.1% below this industry median. Based on the distribution chart, Innovent Biologics ranks #389 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #389 out of 702 companies for Days Payable. This places Innovent Biologics in the lower half of its industry. The industry median Days Payable is 113.10. Innovent Biologics' value of 91.50 is 19.1% below this benchmark. Historically, Innovent Biologics' own Days Payable has ranged from 87.33 to 187.05 over the past decade. While the company's 10-year median is 105.76 vs. the industry median of 113.10, Innovent Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Days Payable of 91.50 is 19.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Days Payable is 91.50, which is 13% below median its own 10-year median of 105.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.19, compared to a current price of €9.69 — trading 13.4% below its estimated fair value. The current Days Payable is 91.50, which is 13% below median its 10-year median of 105.76 and 19.1% below the Biotechnology industry median of 113.10. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current Days Payable is 91.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €9.69 is trading 13.4% below its estimated GF Value™ of €11.19.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
Days Payable: 91.50 (13% below median its 10-year median of 105.76)
GF Value™: €11.19 vs. price of €9.69 (13.4% below fair value)
Industry Position: 19.1% below the Biotechnology median (#389 of 702)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
